As such, the FXR agonist INT747 improves insulin sensitivity and liver function in humans [133], whereas another FXR agonist (WAY-362450) attenuates liver inflammation and fibrosis in a mouse model of fatty liver [134]. Here, NR1H4 is linked to fatty liver disease.